CD Biosynsis offers comprehensive Yeast-Based Assay and Modeling Services , utilizing the genetic tractability and well-characterized biology of Saccharomyces cerevisiae and other yeast species for diverse biological and chemical investigations. Our services integrate robust experimental assays with advanced computational modeling to accelerate drug discovery, protein engineering, and metabolic pathway design. We provide services ranging from high-throughput screening assays for protein-protein interactions (Y2H, Y3H) and drug targets, to in silico metabolic flux balance analysis (FBA) and kinetic modeling. This dual approach provides deep, quantitative insights, allowing for rational design and optimization that dramatically reduces the experimental time and cost associated with complex biological projects.
Get a QuoteYeast offers a simplified eukaryotic background, making it an excellent platform for heterologous expression and analysis of complex gene functions, especially those from mammalian or plant systems. Yeast-based assays provide rapid, cost-effective screening capabilities essential for high-volume drug or protein discovery. Furthermore, its well-annotated genome and metabolism make it perfectly suited for quantitative computational analysis. By combining reliable, scalable assays with predictive modeling, we move projects from hypothesis generation to validated, actionable data much faster than traditional methods, particularly for characterizing large genetic or chemical libraries.
Yeast Two-Hybrid (Y2H) Screening
High-throughput screening to identify novel protein-protein interactions (PPIs) for target identification or pathway mapping.
Drug Target Reporter Assays
Development of customized yeast strains where a target gene's activity is linked to a quantifiable reporter (e.g., fluorescence, growth marker) for compound screening.
Directed Evolution Libraries
Creating and screening large libraries of mutant proteins or pathways in yeast (using FACS or plate readers) to rapidly evolve desired functions or stability.
Flux Balance Analysis (FBA)
Constraint-based modeling using the yeast metabolic network reconstruction to predict maximum theoretical product yield and identify pathway bottlenecks.
Kinetic and Dynamic Modeling
Developing mathematical models to simulate the time-dependent behavior of complex genetic circuits or metabolic pathways under dynamic conditions.
Target Prediction and Pathway Gaps
Using computational tools to suggest optimal gene knockout/knock-in strategies and identify missing enzymatic steps in a synthetic pathway.
Omics Data Integration
Combining transcriptomics, proteomics, and metabolomics data with FBA models to refine predictions and accurately pinpoint non-obvious metabolic bottlenecks.
Machine Learning (ML) Optimization
Applying ML algorithms to assay data to optimize experimental design, predict superior gene combinations, and guide subsequent engineering iterations.
Custom Software Development
Creating user-friendly computational tools tailored to client-specific metabolic pathways or screening data sets.
Automated HTS Readers
Robotic plate readers and liquid handlers capable of rapid, parallel monitoring of yeast assays in 96- and 384-well formats.
Genome-Scale Metabolic Models
Utilization of highly curated models (e.g., Yeast8) for accurate Flux Balance Analysis and in silico simulation.
Cell-Based Biosensors
Leveraging genetically engineered yeast biosensors (fluorescent reporters) to measure specific target molecules inside the cell.
Drug Discovery and Repurposing
Screening chemical libraries against disease-relevant protein targets (humanized in yeast) to identify novel hits and modes of action.
Metabolic Pathway Troubleshooting
Using FBA and kinetic modeling to precisely locate and quantify rate-limiting steps in a synthetic metabolic pathway for bioproduction.
Protein/Enzyme Engineering
Screening directed evolution libraries in yeast to improve enzyme turnover rate, stability, or substrate specificity.
A closed-loop system for generating validated insights.
Consultation & Modeling
Assay Development & HTS
Data Generation & Analysis
Optimization & Reporting
Problem Definition: Define the biological question or target molecule.
In Silico Prediction: Use FBA or kinetic models to propose optimal genetic/chemical targets and assay metrics.
Assay Construction: Develop the specific yeast strain (e.g., Y2H, reporter strain) and validate assay reliability.
HTS Execution: Screen large chemical or genetic libraries using automated liquid handling and plate readers.
Experimental Data: Collect raw HTS data, dose-response curves, or growth kinetics.
Data Interpretation: Integrate experimental results with the initial computational model to check for predictive accuracy.
Learning Phase: Modify the computational model based on experimental results to predict next-round improvements.
Final Report: Deliver a comprehensive report including validated hits, optimized designs, and refined computational models.
Integrated DBTL Cycle
Seamless connection between predictive modeling (Design) and high-throughput experimental validation (Test/Learn).
Rapid HTS Capability
Ability to screen massive compound or mutant libraries quickly and cost-effectively using standardized yeast assays.
Quantitative Metabolic Insights
Deep understanding of flux distribution and bottlenecks provided by FBA, maximizing metabolic engineering success.
Customizable Systems
Assays are fully tailored to express and analyze heterologous proteins from virtually any organism (human, plant, microbe).
"The combination of FBA modeling and subsequent experimental validation precisely identified a non-obvious enzyme bottleneck, allowing us to increase our target compound titer by 70%."
Dr. Liam O’Connell, Lead Bioengineer, Pharmaceutical Precursors
"Their Yeast Two-Hybrid screening service provided a comprehensive interaction map for our viral protein of interest, uncovering several novel human PPIs for future drug targeting."
Ms. Sophia Reyes, Research Scientist, Virology Research
"The custom reporter assay they developed allowed us to screen a chemical library of 15,000 compounds in under two weeks, accelerating our hit identification phase dramatically."
Mr. Peter Xu, R&D Director, Agrochemicals
"We commissioned CD Biosynsis to support an intricate gene editing project with multiple targets. Their talent in producing high-quality work in a short period of time was impressive. Their solutions were custom made to suit our needs, and they went above and beyond to ensure our experiments worked. Their support has been a great asset to our research department and we look forward to further working with them."
Dr. Raj Patel, Principal Investigator, Department of Molecular Biology
"As a pharmaceutical company working to discover new cancer therapies, we require accurate, trustworthy gene editing solutions. CD Biosynsis did more than what we expected when it came to providing strong, accurate CRISPR/Cas9 solutions for our preclinical research. Their technical support team was excellent and responsive, and they quickly replied to our questions. This alliance has been pivotal in helping us move our drug pipeline forward. Thank you, CD Biosynsis, for your amazing service!"
Dr. Clara Rodriguez, Chief Scientist, Pharmaceuticals
What types of proteins can be tested using the Y2H system?
The Y2H system is robust for testing interactions between transcription factors, viral proteins, human signaling proteins, and many other complex protein types, with the advantage of in vivo interaction detection.
Is your Flux Balance Analysis (FBA) based on a specific yeast model?
Yes, our FBA utilizes the highly detailed, current genome-scale metabolic model for Saccharomyces cerevisiae (commonly Yeast8), which is constantly updated and refined with new omics data.
How quickly can you turn around a small-scale HTS assay?
Once the reporter strain is validated, a small-scale HTS (e.g., screening 1,000-5,000 compounds) can typically be completed in 1 to 2 weeks, thanks to our automated platforms.
What data is included in the final computational modeling report?
Reports include the final optimized model structure, calculated maximum theoretical yields, identified reaction bottlenecks, and suggested genetic intervention strategies (KO/KI targets).
How much does Metabolic Engineering services cost?
The cost of Metabolic Engineering services depends on the project scope, complexity of the target compound, the host organism chosen, and the required yield optimization. We provide customized quotes after a detailed discussion of your specific research objectives.
Do your engineered strains meet regulatory standards?
We adhere to high quality control standards in all strain construction and optimization processes. While we do not handle final regulatory approval, our detailed documentation and compliance with best laboratory practices ensure your engineered strains are prepared for necessary regulatory filings (e.g., GRAS, FDA).
What to look for when selecting the best gene editing service?
We provide various gene editing services such as CRISPR-sgRNA library generation, stable transformation cell line generation, gene knockout cell line generation, and gene point mutation cell line generation. Users are free to select the type of service that suits their research.
Does gene editing allow customisability?
Yes, we offer very customised gene editing solutions such as AAV vector capsid directed evolution, mRNA vector gene delivery, library creation, promoter evolution and screening, etc.
What is the process for keeping data private and confidential?
We adhere to the data privacy policy completely, and all customer data and experimental data are kept confidential.
CRISPR-Cas9 technology represents a transformative advancement in gene editing techniques. The main function of the system is to precisely cut DNA sequences by combining guide RNA (gRNA) with the Cas9 protein. This technology became a mainstream genome editing tool quickly after its 2012 introduction because of its efficient, simple and low-cost nature.
The CRISPR gene editing system with its Cas9 version stands as a vital instrument for current biological research. CRISPR technology enables gene knockout (KO) through permanent gene expression blockage achieved by sequence disruption. Various scientific domains including disease modeling and drug screening employ this technology to study gene functions. CRISPR KO technology demonstrates high efficiency and precision but requires confirmation and verification post-implementation because unsatisfactory editing may produce off-target effects or incomplete gene knockouts which impact experimental result reliability. For precise and efficient Gene Editing Services - CD Biosynsis, Biosynsis offers comprehensive solutions tailored to your research needs.
The CRISPR-Cas9 knockout cell line was developed using CRISPR/Cas9 gene editing to allow scientists to remove genes accurately for research on gene function and disease models and pharmaceutical discovery. Genetic research considers this technology essential due to its high efficiency together with simple operation and broad usability.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
|
There is no product in your cart. |
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.